GNLX

#3925
Genelux Corporation Common Stock
2.64 USD
+4.35%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
2.64
2.64
1年のレンジ
2.25
8.54
1日の変化
+4.35%
月次変化
0.00%
6か月変化
-50.00%
1年の変化
+5.18%
以前の終値
2.53
始値
2.64
Bid
Ask
安値
2.64
High
2.64
ボリューム
9
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 118.29 M
  • Employee 26
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-5.07
売上高対価格比率
20.26 K

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

ニュース